Product Watch, October 2008

Article

Product watch, October 2008

Please click on any of the headlines below to see the full story.

UK reimburses Lucentis… at last!
The UK's medical reimbursement governing body, the National Institute for Health and Clinical Excellence (NICE), is to reimburse Lucentis (ranibizumab; Novartis) jointly with Novartis under a dose-capping scheme, reversing NICE's earlier, much derided, decision not to reimburse the drug. 

Cardiovascular drug might treat diabetic retinopathy
A drug that has traditionally been used to treat cardiovascular conditions has shown promise in the treatment and prevention of diabetic retinopathy. The claim was based on data from a large-scale programme assessing the effect of an angiotensin receptor blocker (ARB) on the incidence and progression of diabetic eye disease. Findings from the study will be published in The Lancet

 

For up-to-date news and announcements, please check the latest news section of our website. Alternatively, please sign up for our weekly newsletter.

Recent Videos
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
AAO 2024: Bonnie An Henderson, MD, talks about advancing medical education with AI, robotics, and diverse learning methods
© 2024 MJH Life Sciences

All rights reserved.